

→ MRP's / TP 8/24/03
 P. amm. No
 Specific
 5/16/2003

SUBSTITUTED PYRIDOINDOLES AS SEROTONIN AGONISTS AND ANTAGONISTS

RELATED APPLICATIONS


5 This is a continuation-in-part of U.S. Application Serial No. 10/026,611, filed December 19, 2001, that claims the benefit of U.S. Provisional Application Serial No. 60/256,740, filed December 20, 2000, the contents of which are herein incorporated by reference.

10

FIELD OF THE INVENTION

The present invention is directed to certain novel compounds represented by structural Formula (I)

15



(I)

or pharmaceutically acceptable salt forms thereof, wherein R¹, R⁵, R⁶, R⁷, R⁸, R⁹, X, b, k, and n, and the dashed line are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

BACKGROUND OF THE INVENTION

There exists a substantial correlation for the relationship between 5-HT₂ receptor modulation and a variety of diseases and therapies. To date, three subtypes of the 5-HT₂ receptor class have been identified, 5-HT_{2A}, 5-HT_{2B}, and 5-HT_{2C}. Prior to the early 1990's the 5-HT_{2C} and 5-HT_{2A} receptors were referred to as 5-HT_{1C} and 5-HT₂, respectively.



23914

PATENT TRADEMARK OFFICE


TITLESUBSTITUTED PYRIDOINDOLES AS SEROTONIN AGONISTS AND
ANTAGONISTS.

5

ABSTRACT

The present invention is directed to certain novel compounds represented by structural Formula (I)

10



or pharmaceutically acceptable salt forms thereof, wherein R¹, R⁵, R⁶, R⁷, R⁸, R⁹, X, b, k, and n, and the dashed lines are described herein. The invention is also

15 concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia,
20 sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.